Oligodendrocytes are essential regulators of axonal energy homeostasis and electrical conduction and emerging target cells for restoration of neurological function. Here we investigate the role of protease activated receptor 2 (PAR2), a unique protease activated G protein-coupled receptor, in myelin development and repair using the spinal cord as a model. Results demonstrate that genetic deletion of PAR2 accelerates myelin production, including higher proteolipid protein (PLP) levels in the spinal cord at birth and higher levels of myelin basic protein and thickened myelin sheaths in adulthood. Enhancements in spinal cord myelin with PAR2 loss-of-function were accompanied by increased numbers of Olig2-and CC1-positive oligodendrocytes, as well as in levels of cyclic adenosine monophosphate (cAMP), and extracellular signal related kinase 1/2 (ERK1/2) signaling. Parallel promyelinating effects were observed after blocking PAR2 expression in purified oligodendrocyte cultures, whereas inhibiting adenylate cyclase reversed these effects. Conversely, PAR2 activation reduced PLP expression and this effect was prevented by brain derived neurotrophic factor (BDNF), a promyelinating growth factor that signals through cAMP. PAR2 knockout mice also showed improved myelin resiliency after traumatic spinal cord injury and an accelerated pattern of myelin regeneration after focal demyelination. These findings suggest that PAR2 is an important controller of myelin production and regeneration, both in the developing and adult spinal cord. 
feature of neurological injury and disease (Gingrich & Traynelis, 2000; Radulovic et al., 2013; Scarisbrick et al., 2008) .
Abnormalities in CNS PAR activating enzymes may occur after extravasation and/or secretion by CNS endogenous, or infiltrating immune cells. For example, the canonical activator of protease activated receptor 1 (PAR1), thrombin, is elevated in the CNS in the context of injury and disease (Arai, Miklossy, Klegeris, Guo, & McGeer, 2006; Chen et al., 2012; Citron, Smirnova, Arnold, & Festoff, 2000; Radulovic, Yoon, Wu, Mustafa, & Scarisbrick, 2016; Yoon et al., 2013) .
Our recent studies demonstrated that PAR1 knockout mice show accelerated patterns of myelination developmentally, thickened myelin sheaths, and higher levels of myelin basic protein in adulthood (Yoon, Radulovic, Drucker, Wu, & Scarisbrick, 2015) . Moreover, we showed that targeting PAR1 genetically or pharmacologically could effectively reduce dysmyelinating effects of PAR1 over activation (Burda, Radulovic, Yoon, & Scarisbrick, 2013) . Given these findings, we hypothesized that protease activated receptor 2 (PAR2) may likewise be highly relevant to the myelination program, particularly since it is preferentially activated by a number of proteases enriched in the CNS, including kallikrein 6 (also referred to as neurosin). Kallikrein 6 is a secreted serine protease that is abundant in CNS white matter (Scarisbrick et al., 2000 (Scarisbrick et al., , 2002 (Scarisbrick et al., , 2006a Scarisbrick, Isackson, Ciric, Windebank, & Rodriguez, 2001; Scarisbrick, Towner, & Isackson, 1997) , and is one of the most up regulated genes (6.5-fold) upon oligodendrocyte differentiation (Cahoy et al., 2008) . Kallikrein 6 is also elevated in MS patient sera , and CSF (Hebb, Bhan, Wishart, Moore, & Robertson, 2011; Schutzer et al., 2013; Singh et al., 2015) , and coordinately elevated along with PAR2 (Noorbakhsh et al., 2006) in MS lesions (Scarisbrick et al., 2001) , and after traumatic spinal cord injury (SCI) Yoon et al., 2013) .
The myelin production program is dynamic and tightly controlled by cell-intrinsic and extrinsic factors directing a delicate balance of positive or negative regulatory effects (Kremer, Gottle, Hartung, & Kury, 2016) . There is an innate capacity for myelin regeneration centered on widely distributed oligodendrocyte progenitors cells (OPCs) . OPCs are also present within demyelinated MS plaques, but differentiation failure is common (Irvine & Blakemore, 2008; Patrikios et al., 2006; Smith, Blakemore, & McDonald, 1979) . Given the accumulating evidence that PAR2 and its activators are also present in MS lesions, we hypothesized that PAR2 may serve as an essential regulator of the myelin production program. Since there are currently no therapies to effectively protect myelin, or to promote myelin regeneration, there is a great need to identify druggable target proteins that are integral regulators governing myelin production.
To evaluate the regulatory actions of PAR2 in myelination, we determined the impact of PAR2 loss-of-function on myelin development and repair using the developing and adult spinal cord as experimental model systems. Our findings reveal that PAR2 is a negative regulator of myelination with PAR2 knockout mice exhibiting an accelerated appearance of oligodendrocytes and proteolipid protein (PLP) during spinal cord development. The regulatory role of PAR2 extended into adulthood with thicker myelin membranes in PAR2 knockout mice, including higher levels of myelin basic protein (MBP). Evidence is presented that genetic or pharmacological blockade of PAR2 removes a physiologic brake to unleash an adenylate cyclase-linked myelination program that is associated with elevations in ERK1/2, and which can be modulated by BDNF. Moreover, genetic targeting of PAR2 fostered myelin regeneration in the adult spinal cord, and was associated with myelin preservation after traumatic spinal cord injury. These are the first studies to identify PAR2 as a key suppressor of myelination, both in the developing and adult spinal cord, and to identify this unique receptor as a potential new drug target to promote myelin protection and repair. https://www.jax.org/strain/000664) for more than 40 generations . All mice were obtained from The Jackson Laboratory (Bar Harbor, ME). PAR2
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1/1 littermates served as controls. An equal number of male and female mice were used in studies examining the impact of PAR2 on myelin development in vivo and in vitro and in the studies of lysophosphatidylcholine-medicated focal demyelination and remyelination. Studies examining the impact of PAR2 on recovery after traumatic spinal cord injury involved female mice . All animal experiments were carried out with adherence to NIH Guidelines for animal care and safety and were approved by the Mayo Clinic Institutional Animal Care and Use Committee.
| Developmental regulation of PAR2 in the spinal cord
To begin to address the significance of PAR2 to myelination of the spinal cord, we quantified the expression of PAR2 RNA in the spinal cord of mice at P0, 7, 21, or 45 using real-time PCR .
RNA was isolated using RNA Friendswood, TX) 2008), or a PAR2 antagonist (GB88, 5 mM, University of Queensland, Brisbane, Australia) (Barry et al., 2010; Lohman et al., 2012a,b) . In each case, freshly isolated OPCs were plated and allowed to adhere for 3 h before application of the PAR2 agonist, or antagonist, for a 72 h period of differentiation. The contribution of adenylate cyclase to the promyelinating effects of GB88 was determined by co-application of the adenylate cyclase inhibitor SQ22536 in parallel experiments (100 mM, 568500, Sigma-Aldrich). In addition, we evaluated whether BDNF, a neurotrophin well recognized to participate in synaptic plasticity in a cAMP-dependent manner (Ji, Pang, Feng, & Lu, 2005) , and to exert promyelinating effects (Fulmer et al., 2014) , can overcome the ability of PAR2-activation to suppress myelin gene expression. BDNF (10 ng/ mL, Peprotech Rocky Hill, NJ) or SQ22536 were co-applied with agonists or antagonists. The level of RNA encoding PAR2, MBP, PLP, NogoA, or Olig2 was determined in 0.10 lg of RNA in triplicate using an iCycler iQ5 system (BioRad) with primers described in Table 1 ( Yoon et al., 2015) . Results were repeated twice from independent cell preparations with parallel results. The relative amount of RNA in each case was normalized to the constitutively expressed gene Rn18S.
| Quantification of spinal cord cAMP
To test the hypothesis that PAR2 may suppress myelin production by blocking the activity of adenylate cyclase, we measured levels of the second messenger cyclic adenosine monophosphate (cAMP) in the spinal cord of PAR2 1/1 and PAR2 2/2 at the P21 peak of myelin production. cAMP levels were quantified using a direct cAMP ELISA kit (Enzo Life Sciences, Farmingdale, NY).
| Analysis of myelin thickness
The thickness of myelin sheaths was determined by structural and ultrastructural analysis of the spinal cord dorsal column white matter at P45. Mice were perfused with Trump's fixative (4% formaldehyde with 1% glutaraldehyde, pH 7.4) and a 1 mm segment of the cervical spinal cord was osmicated and embedded in araldite. Myelin sheath thickness in the dorsal column of the cervical spinal cord at P45 was quantified in ultrathin (0.1 mm) sections taken from araldite blocks using a JEM-1400 Transmission Electron Microscope (JEOL USA, Peabody, MA).
Images were captured at 80003 without knowledge of genotype and included six fields across the dorsal-ventral axis of the dorsal column.
G-ratios were calculated from all myelinated axons in each image and this included axons with diameters ranging from 0.6 to 6 mm. Across three animals per time point this resulted in measurement of roughly 2300 myelinated fibers for each genotype. Measurements of axon diameter (d) and myelin fiber diameter (D) were made by including axons of all diameters using Image J software and presented as mean
, or myelin thickness 6 SE. Since very few axons were 4 mm, the mean values calculated in each case included only those axons <4 mm. This analysis parallels methods used in in prior studies (Furusho, Dupree, Nave, & Bansal, 2012; Ishii, Furusho, & Bansal, 2013; Ishii, Fyffe-Maricich, Furusho, Miller, & Bansal, 2012) , facilitating comparison of results.
2.8 | Evaluation of locomotor activity in PAR21/1 and PAR2 2/2 mice Potential differences in locomotor activity between PAR21/1 and PAR2 2/2 mice were evaluated using a Comprehensive Laboratory Animal Monitoring System (Columbus Instruments, Columbus, OH). Animals were housed in the system and total activity, ambulatory activity, and rearing data collected for a period of 72 h that included a 24 h period of acclimation followed by 24 h fed and 24 h fasted periods.
The mean activity across genotypes in each case (PAR2 1/1 , n 5 11 or PAR2 2/2 , n 5 12) was analyzed for light and dark periods under both fed and fasted conditions.
.9 | COM P RE SSION SP INA L COR D IN J U RY
The effect of PAR2-loss-of-function on spinal cord myelin after traumatic injury was examined in mice with contusion-compression SCI as previously described . Briefly, SCI at the level of L2/L3 was generated in 12-week old (19-23 g) adult female PAR2 (Joshi & Fehlings, 2002; Radulovic et al., 2013; Yu & Fehlings, 2011) . This model generates a severe injury with both an initial contusion as well as a persistent dorsal and ventral compression that results in robust neuroinflammatory responses, astrogliosis and axon degeneration (Yu & Fehlings, 2011) . Analysis of changes in myelin in PAR2 1/1 and PAR2 2/2 mice were made in the same protein homogenates and tissue specimens that were used for examination of inflammatory astrogliosis, neurodegenerative responses, and neurobehavioral recovery reported in our recent publication demonstrating improvements in neurobehavioral outcomes in mice lacking the PAR2 gene. Here we extend these studies to additionally determine the expression of MBP at 3 and 30 dpi in spinal segments encompassing the injury epicenter, above and below. Also, tissue sections from additional groups of wildtype and PAR2 2/2 mice at 31 dpi were immunostained to quantify potential differences in the number of Olig2 and CC-1 oligodendrocytes.
| Lysophosphatidyl choline model of remyelination
To determine the impact of PAR2 on myelin regeneration, 6 mL of a 1% and a dorsal laminectomy performed between the T6 and T9 vertebrae, allowing for lysolecithin injection at T11-T12. All mice were randomized prior to surgery and the surgeon blinded to genotype. Lysolecithin in saline was injected into the dorsal column using a 30-70 mm glass micropipette at a rate of 1.2 mL/min using a stereotaxic microinjection system (Stoelting, Wood Dale, IL). Buprenorphine (0.05 mg/kg, Hospira, Lake Forest, IL) was given intraperitoneally postoperatively to minimize 
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| PAR2 loss-of-function increases oligodendrocyte numbers in early development
The highest levels of PAR2 expression in the developing spinal cord occurred at P21 when levels were 1.4-fold higher than those observed on P0 (Figure 1 , p < .01, NK). At P7, there was a slight reduction in PAR2 expression compared to that observed on P0 (p < .001, NK). To shed light on any differences in PAR2 expression associated with OPCs at early stages of myelin production compared to mature myelinating cells, we used immunofluorescence techniques to localize PAR2 to Olig21 or CC-11 oligodendrocytes, respectively, at the P21 peak of myelin production. First, we observed that 59 6 6% of all DAPI1 cells in the spinal cord dorsal column were PAR21. Next, we found that 73.8 6 5% of all DAPI1 cells were Olig21, 69 6 4% were CC-11, and 57 6 3% were both Olig2 and CC-11. Of the PAR21 cells, 52 6 5%
were Olig21, 50 6 4% were CC11, and 47% 6 4% were positive for all three markers. These findings suggest that at the P21 peak of spinal cord myelination, approximately equal numbers of OPCs and young oligodendrocytes (Olig21), and mature CC-11 oligodendrocytes, express PAR2. While these results suggest that the majority of PAR21 cells in spinal cord white matter are oligodendrocytes, approximately 12% of all PAR21 cells were not stained for either oligodendrocyte marker.
Based on prior studies it is likely that the nonmyelin related PAR21
cell types in the spinal cord white matter are astrocytes or microglia (Noorbakhsh et al., 2006; Radulovic et al., 2015) .
To determine whether increases in PLP and MBP protein in the spinal cord of PAR2 2/2 mice reflect potential increases in myelin protein expression per cell, or alternatively, more myelin producing oligodendroglia, we quantified the number of Olig2 and CC-1-immunopositive cells ( Figure 1E -H). The number of Olig21 cells in the dorsal column white matter was 1.4-fold greater in PAR2 2/2 at P7 compared to wildtype controls (p 5 .007, NK, Figure 1E ). Olig21 cells were also elevated in the lateral column white matter at P7 and at P21 (p < .04, NK, Figure 1G ). Overall spinal cord Olig2 protein levels detected by Western blot were also higher in spinal cords of PAR2 2/2 compared to PAR21/1 mice at P7 (2.2-fold, p < .001, NK, Figure 2E ).
The number of CC-1-immunoreactive mature oligodendrocytes was also increased on P7 in the dorsal column white matter of PAR2
2/2 mice (1.2 to 1.5-fold, p 5 .02, NK, Figure 1F ). The number of CC-1-positive oligodendrocytes was 1.3-fold lower in PAR2 2/2 mice at P21 compared to PAR21/1 mice (p < .05, NK). In the lateral column white matter, elevations in CC-11 oligodendrocytes were observed on P0, P7, and P21 (1.3 to 2-fold, p .03, NK, Figure 1H ). Despite the accelerated appearance of Olig21 and CC-11 oligodendrocytes in PAR2 knockout mice, numbers were identical across genotypes at P45. cord on P7 compared to wildtype. Increases in the promyelination signaling pathway ERK1/2 was also observed by P7, on P21, and in adulthood (h, i). No significant differences in NF H (f), or NF L (g), were observed in the same spinal cord samples. Levels of total AKT were significantly elevated in PAR2 2/2 mice on P7 (n). ROD readings for pERK and pAKT were normalized to total protein or to actin (i-k). Actin was probed on every membrane to control for loading and is shown for the corresponding membrane in the lower panel in (a) and (h) (*p < .05, **p .01, ***p .001 Newman Keuls; ND, not detected). Footnote to Figure 2 : The western blots presented in Figure 2 showing quantification of myelin associated proteins and signaling molecules in wildtype and PAR2 knockout mouse spinal cords, were blotted alongside protein from PAR1 knockout spinal cords. The blots related to developmental changes in myelin proteins in PAR1 knockout spinal cord were published versus wildtype mice in Yoon et al. (2015) . Therefore, the blots for PLP, CNPase, Olig2, neurofilament ERK1/2, and actin in wildtype mice (only) can also be found in our prior publication. The findings related to PAR2 have not been previously published ERK1/2 signaling being associated with enhanced myelination, we observed significantly higher levels of activated ERK1/2 in the spinal cords of PAR2 2/2 mice at P7, P21 and adulthood, compared to wildtype controls ( Figure 2H -K). Elevated expression of activated ERK1/2 peaked in both genotypes at P21, but was 1.7-fold higher in the spinal cord of mice with PAR2 loss-of-function (p 5 .01, NK). Elevated levels of activated ERK1/2 were also detected in PAR2 2/2 spinal cords on P7, when levels were 12.9-fold higher than wildtype (p 5 .02, Newman Keuls). Levels of total AKT were higher in PAR2 2/2 spinal cords on P7 (p 5 .01, NK). There was also a strong trend for increased levels of phosphorylated AKT at P0 and P7, but these elevations did not reach the level of statistical significance. While we do not assume that all of the elevations in ERK and AKT signaling observed in the developing spinal cord are associated with myelinating cells, the temporal changes observed do correspond to the accelerated patterns of myelin production observed in the spinal cords mice lacking PAR2. Future studies will be needed to immune localize elevations in ERK and AKT signaling to myelinating cells.
| PAR2 loss-of-function enhances oligodendrocyte differentiation in vitro
To determine whether reductions in oligodendrocyte PAR2 may directly impact oligodendrocyte differentiation, we evaluated the appearance of myelin-associated proteins in OPCs, derived from wildtype or PAR2 2/2 mice, in cell culture (Figure 3) 
| PAR2 regulates myelin thickness in the adult spinal cord
To determine whether increases in myelin protein expression in the adult spinal cord were reflected in myelin thickness, we used ultrastructural approaches to evaluate g ratios with the dorsal column white matter (Figure 4 we evaluated overall motor activity, ambulation, and rearing during diurnal and nocturnal cycles under both fed and fasted conditions using a comprehensive laboratory animal monitoring system ( Figure 5 ). Overall activity of mice lacking PAR2 was increased at night under fed (1.4-fold) or fasted (1.8-fold) conditions ( Figure 5A ). In addition, both nocturnal ambulation ( Figure 5B ) and rearing responses ( Figure 5C ) were also increased in PAR2-deficient mice under fed or fasted conditions (1.5-to 2-fold, p .05 Student's unpaired t test, Figure 5B ,C). Despite these differences in nocturnal activity, diurnal rhythms did not differ across genotypes ( Figure 5D ).
| PAR2 loss-of-function improves myelin integrity after traumatic SCI
To determine whether the promyelination effects of PAR2 loss-offunction also occur in the context of CNS injury, we compared the appearance of myelin markers in an experimental model of contusioncompression spinal cord injury ( Figure 6 ). SCI was induced in P90 mice such that all mice were P120 at the 30 dpi end point examined. Mirroring the 1.5-fold elevation in MBP protein observed in the intact spinal cord of P45 PAR2 2/2 mice relative to PAR2 1/1 (Figure 2 ), MBP protein levels were threefold higher in the uninjured spinal cord of PAR2 2/2 mice at P120 (p 5 .001, NK). At 3 dpi, MBP protein levels were 3.7-fold higher in spinal segments above the injury epicenter, and twofold higher at the injury epicenter, in mice with PAR2 loss-offunction compared to mice with an intact PAR2 signaling system (p .04, NK). At 30 dpi, MBP protein levels above the injury epicenter were 2.4-fold higher in PAR2 2/2 compared to wildtype mice (p 5 .02, NK).
To determine whether differences in myelin abundance in P120 PAR2 2/2 mice before and after SCI are reflected in differences in the number of myelinating cells, counts of Olig2 and CC-11 cells were made in spinal segments above the lesion epicenter ( Figure 6 ). trend towards retention of a greater number of Olig2 and CC-1 oligodendrocytes in mice lacking PAR2, but the differences were not statistically significant.
| PAR2 loss-of-function facilitates myelin regeneration
The potential impact of PAR2 loss-of-function on myelin repair in the adult spinal cord was evaluated by making counts of remyelinated axons 14 days after lysophosphatidyl choline-mediated induction of a focal demyelinating lesion in the dorsal column white matter (Figure 7 ).
We first confirmed that mean size of focal demyelination was similar in Histograms show the mean g ratios and myelin thickness for axons across a range of diameters, demonstrating that the most significant increases in myelin thickness were observed in axons ranging from 0.5 to 1 mm (p 5 1.5 3 10 26 , Student's t test) (scale bar, C 5 0.2 mm).
(c) Representative electron micrographs taken from the spinal cord dorsal column white matter of PAR21/1 or PAR2 2/2 mice at P45.
Micrographs were used to calculate g ratios and myelin thickness, which were plotted relative to axon diameter
lesions in mice lacking PAR2 contained 1.6-fold more Olig21-, and 1.2-fold more CC-11-immunopositive oligodendrocytes, compared to their wildtype counterparts (p .04, Student's t test). These results suggest that inhibition of PAR2 may be a useful approach to accelerating myelin regeneration in the adult spinal cord.
| D I SCUSSION
These studies identify PAR2 as a key regulator of myelin development along with myelin resiliency and regeneration in the adult CNS. PAR2 knockout mice exhibit enhancements in myelin production developmentally and after demyelination, suggesting that this receptor serves as an innate suppressor of the myelin production program across the lifespan. In addition, loss-of-PAR2 function supports a level of myelin reserve in the adult spinal cord that renders it more resilient to the demyelinating effects of spinal cord trauma, possibly contributing to the improvements in cellular, molecular, and behavioral outcomes previously observed in PAR2 null mice after SCI .
Results demonstrate that PAR2 is uniquely positioned as a target for therapies aimed at improving the capacity for myelin production, preservation, and regeneration in the developing and adult CNS.
PAR2 loss-of-function accelerates the production of oligodendrocytes and PLP in the developing spinal cord and results in higher levels of MBP and thickened myelin sheaths in adulthood. Greater numbers of Olig2-and CC-1-positive oligodendrocytes were observed by P7 in PAR2 knockout mice, but not at earlier time points, suggesting this receptor regulates the speed of oligodendrocyte differentiation rather than exclusively the number of oligodendrocytes generated. In conjunction with this, we observed temporally discrete enhancements in PLP in the spinal cord at birth, and in MBP in adulthood. Thus the removal of a single receptor can specifically impact on the two major myelin structural proteins located on unique chromosomes, suggesting that PAR2 is an integral intersection point capable of serving as a fundamental regulator of unique aspects of myelin production. Despite these changes in myelin, there were no significant alterations in the heavy or light chains of neurofilament at any age examined, suggesting that the enhancements in myelin observed in PAR2 2/2 mice were not dependent on, nor did they result in obvious changes in axons. The ), or pharmacologically (GB88) (Barry et al., 2010) , resulted in significantly increased expression of PLP, MBP, and NogoA.
Evidence is presented here to suggest that the mechanism by which PAR2 loss-of-function enhances myelin production is related to an ability to inhibit cAMP production. First, we discovered that cAMP levels are elevated by more than two-fold in the spinal cord of mice lacking PAR2. cAMP is a pleiotropic second messenger generated by adenylate cyclase, an enzyme whose activity can be increased or decreased by a variety of hormone and growth factor signaling loss-of-function at base line ((c), control), and at 3 and 30 dpi. MBP levels were higher in spinal segments at the injury epicenter (e) and above (a) at 3 dpi, and in spinal segments above at 30 dpi in PAR2 2/2 relative to those with an intact PAR2 signaling system (c, below the injury epicenter). Photomicrographs and associated histograms (c-f), demonstrate that the number of Olig21-and CC-11-oligodendrocytes was higher in the spinal cord of PAR2 2/2 compared to PAR2 1/1 mice at baseline (C, control) (scale bar (c) and ( mechanisms. With regard to myelination, it is well recognized that increasing adenylate cyclase activity promotes oligodendrocyte differentiation (Raible & McMorris, 1990 ). While we have not pinpointed the elevations in spinal cord cAMP in PAR2 2/2 mice to myelinating cells, the current findings taken with prior studies point to a model in which loss-of-PAR2 function diminishes Gai-mediated inhibition of adenylate cyclase, resulting in increased cAMP and myelin production (Figure 8 ).
For example, PAR2 is known to signal through Gai to inhibit adenylate cyclase in smooth muscle cells (Sriwai, Mahavadi, Al-Shboul, Grider, & Murthy, 2013) . Also, we showed that BDNF, a growth factor known to elevate cAMP, prevented decreases in PLP expression observed in OPC cultures treated with a PAR2 activating peptide. We also showed that a small molecule inhibitor of PAR2 (GB88) increases OPC myelin gene expression and that these effects were diminished by an adenylate cyclase inhibitor (SQ22536). Interestingly, the ability of GPR17 (Simon et al., 2016) , and GPR37 (Yang, Vainshtein, Maik-Rachline, & Peles, 2016) to block myelin production was also recently linked to a G protein-mediated suppression of adenylate cyclase. These findings suggest that PAR2 activators, such as kallikrein 6 that are found in MS lesions (Scarisbrick et al., 2002) , and at other sites of neural injury including SCI (Scarisbrick et al., 2006b; Yoon et al., 2013) , may impede myelin repair by suppressing adenylate cyclase activity.
The 'promyelinating' effects of the PAR2 antagonist GB88 in vitro are encouraging, singling out PAR2 as a new potential therapeutic target for demyelinating conditions affecting the developing and adult CNS. While the signaling pathway(s) that GB88 targets downstream of PAR2 in OPCs to foster myelin gene expression were not studied in detail, the fact that these effects were diminished by SQ22536 suggests that adenylate cyclase plays a role. In other studies, GB88 has been shown to selectively inhibit Gq11, Ca
21
, and PKC signaling, and to lead to anti-inflammatory activity in vivo. In addition, GB88 may also activate ERK and Rho, at least in some cell types (Suen et al., 2014) .
Although the precise signaling mechanisms have not been fully detailed, the current studies taken with findings that GB88 exhibits anti-inflammatory activity in vivo in rodent models of arthritis, (Lohman et al., 2012a) and inflammatory bowel disease, (Lohman et al., 2012b) , provides considerable promise that PAR2 small molecule inhibitors have therapeutic potential for a vast range of conditions, including conditions affecting myelin development and myelin regeneration.
Adult mice with PAR2 loss-of-function show improvements in the abundance of MBP at acute and chronic time points after SCI. The preservation of myelin after traumatic SCI in PAR2 2/2 mice may reflect in part a greater number of Olig2 and CC-11 oligodendrocytes in the spinal cord at baseline. Also, given the co-ordinate elevations in many proteases capable of activating PAR2, such as kallikrein 6 at sites of spinal cord trauma Scarisbrick et al., 2006b; Yoon et al., 2013) , the absence of PAR2 may protect myelinating cells from protease-mediated myelin loss, including by way of a direct receptor-dependent suppression of myelin gene expression . Indeed, here we show that selective activation of PAR2 suppresses PLP production in OPC cultures. Altogether, these new findings raise the intriguing possibility that the improvements in molecular, histopathological, and locomotor outcomes that we observe in PAR2 2/2 mice after SCI , including preservation of corticospinal axons, may relate to improvements conferred by increases in the abundance of oligodendrocytes and their progenitors, and to higher levels of myelin preservation. , impedes the activity of adenylate cyclase and hence cAMP production, thereby reducing myelin production. Supporting this, a PAR2-activating peptide (PAR2-AP, SLIGRL-NH2), reduced PLP expression in primary oligodendrocyte cultures and this effect was overcome by BDNF, a promyelinating growth factor that elevates cAMP. Also, blocking the activity of PAR2 by genetic deletion of the receptor increased spinal cord cAMP, and ERK1/2 phosphorylation, and was associated with significant enhancements in markers of myelin membrane differentiation, including PLP and MBP, in vivo and in purified oligodendrocyte cultures. Further linking the promyelinating effects of PAR2 loss-of-function to its ability to inhibit adenylate cyclase, the enhancements in myelin production observed in PAR2 2/2 OPCs were replicated by application of a PAR2 small molecule inhibitor (GB88) to PAR21/1 cultures, an effect that was impeded by application of the adenylate cyclase inhibitor SQ22536. Since cAMP is a pleiotropic molecule that also activates PKA, in addition to other signaling pathways, more studies will be needed to fully define the mechanism(s) by which blocking PAR2 enhances myelination developmentally, in addition to myelin regeneration and myelin reserve in the adult spinal cord [Color figure can be viewed at wileyonlinelibrary.com] demyelination. Enhancements in myelin regeneration were paralleled by increased numbers of Olig2 and CC-1 positive oligodendrocytes.
Taken together these findings demonstrate that blocking PAR2 may be a novel approach to enhancing myelin resiliency and myelin regeneration in the adult spinal cord, raising the possibility of pharmacological modulation of PAR2 as a new therapeutic strategy for treating SCI and other neurological conditions.
One limitation of the current study is that we have used mice with complete PAR2 knockout. While this approach has the potential to mimic the effects of administration of a PAR2 inhibitor, it does not permit us to specifically address the cellular mechanism(s) underlying the promyelinating effects observed. In the CNS, PAR2 is also expressed by at least some neurons, in addition to astrocytes and microglia, especially in the context of injury (Noorbakhsh et al., 2005 (Noorbakhsh et al., , 2006 Radulovic et al., 2015 Radulovic et al., , 2016 . Moreover, PAR2 is widely distributed in peripheral organs, including the kidney, spleen and gastrointestinal system (D 'Andrea et al., 1998) . Thus, while the current findings do demonstrate that mice lacking PAR2 show enhancements in myelination developmentally and after injury in adulthood, whether these effects are dependent on changes in PAR2 in myelinating cells alone, or alternatively, or additionally depend on loss-of-PAR2 function in other cell types, awaits investigation of myelination in mice with cell specific PAR2 knockdown.
We recently reported that mice with PAR1 loss-of-function also show enhancements in spinal cord myelination developmentally . . Whether PAR1 or PAR2 will serve as a more amenable target to foster myelination and myelin repair, and whether targeting these receptors in unison would promote additive promyelinating effects, awaits additional study.
| SU M M A R Y
These studies identify PAR2 as a central biological signaling node that is important in controlling myelination in the developing and adult spinal cord. In the proposed model, PAR2 can be blocked during myelin development or after injury in adulthood to foster myelin production.
Results link PAR2 to myelinogenesis through adenylate cyclase and ERK1/2 signaling, identifying a new and important role for PAR2 as an integral regulator of myelin dynamics. These studies also provide a new mechanistic link between the actions of extracellular proteases, myelination, and cellular repair. Findings are relevant to myelin generation in protection, repair and regeneration in SCI and neurological diseases, and strongly implicate PAR2 as a possible therapeutic target for myelin regeneration and intervention in CNS disease pathology. 
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